These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11422944)

  • 1. Pathogen inactivation of labile blood components.
    Prowse C; Robinson AE
    Transfus Med; 2001 Jun; 11(3):147. PubMed ID: 11422944
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogen inactivation of labile blood products.
    Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components
    Transfus Med; 2001 Jun; 11(3):149-75. PubMed ID: 11422945
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy with blood and blood products].
    Kreienbühl G
    Urologe A; 1996 Jan; 35(1):69-85. PubMed ID: 8851853
    [No Abstract]   [Full Text] [Related]  

  • 4. [Can virus safety of blood products be assured?].
    Krusius T
    Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931
    [No Abstract]   [Full Text] [Related]  

  • 5. Blood safety and nucleic acid testing in Europe.
    Laperche S
    Euro Surveill; 2005 Feb; 10(2):3-4. PubMed ID: 15735316
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral inactivation of blood components: recent advances.
    Horowitz B; Ben-Hur E
    Transfus Clin Biol; 1996; 3(1):75-7. PubMed ID: 8640317
    [No Abstract]   [Full Text] [Related]  

  • 7. JAMA patient page. Avoiding diseases transmitted by blood and body fluids.
    JAMA; 2000 Jul; 284(2):268. PubMed ID: 10917793
    [No Abstract]   [Full Text] [Related]  

  • 8. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP).
    Chamfly V
    Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148
    [No Abstract]   [Full Text] [Related]  

  • 9. What is safe blood?
    Kapoor D; Sarin SK
    J Assoc Physicians India; 2000 Mar; 48(3):335-42. PubMed ID: 11229123
    [No Abstract]   [Full Text] [Related]  

  • 10. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views.
    Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viral inactivation of cellular blood products].
    Andreu G
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):215-6. PubMed ID: 8337130
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transfusion medicine in unified Europe].
    Grigutsch V
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():12-5. PubMed ID: 7841774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion safety--the Ba Con Study.
    Barlow JF
    S D J Med; 1998 May; 51(5):151-2. PubMed ID: 9613194
    [No Abstract]   [Full Text] [Related]  

  • 16. Inactivation of viruses found with cellular components.
    Horowitz B; Valinsky J
    Biotechnology; 1991; 19():431-50. PubMed ID: 1786477
    [No Abstract]   [Full Text] [Related]  

  • 17. [Transfusion medicine--Scandinavian recommendations].
    Jørgensen J; Jensson O; Eklund J; Kornstad L; Messeter L
    Nord Med; 1994; 109(2):61-3. PubMed ID: 8121792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics of pathogen inactivation technology for platelet concentrates in Japan.
    Staginnus U; Corash L
    Int J Hematol; 2004 Nov; 80(4):317-24. PubMed ID: 15615255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First, do no harm.
    Hall AJ
    Trop Med Int Health; 2000 Feb; 5(2):79-80. PubMed ID: 10747264
    [No Abstract]   [Full Text] [Related]  

  • 20. Q&A about reporting of blood-borne virus infection.
    Alta RN; 2009; 65(5):19-21. PubMed ID: 19639806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.